Clinical Trial

Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

Study acronym: PROACT 3
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-20; most recent amendment 2026-03-19.
Status change: Not Yet Recruiting → Recruiting 2025-11-03
Trial Details
NCT Number NCT07087431
Lead Sponsor Massachusetts General Hospital
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Coronary Artery Disease
Enrollment 500 participants
Start Date 2025-10-15
Primary Completion 2026-10-15 (estimated)
Study Completion 2027-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-23